Preparation and Evaluation of [ 18 F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [ 68 Ga]Ga-DOTA/NOTA-NOC.

التفاصيل البيبلوغرافية
العنوان:	Preparation and Evaluation of [ ¹⁸ F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [ ⁶⁸ Ga]Ga-DOTA/NOTA-NOC.
المؤلفون:	Dam JH; Department of Nuclear Medicine, Odense University Hospital, Kløvervænget 47, DK-5000 Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, J.B. Winsløws Vej 19, DK-5000 Odense, Denmark., Langkjær N; Department of Nuclear Medicine, Odense University Hospital, Kløvervænget 47, DK-5000 Odense, Denmark., Baun C; Department of Nuclear Medicine, Odense University Hospital, Kløvervænget 47, DK-5000 Odense, Denmark., Olsen BB; Department of Surgical Pathology, Zealand University Hospital, Sygehusvej 10, DK-4000 Roskilde, Denmark., Nielsen AY; Department of Nuclear Medicine, Odense University Hospital, Kløvervænget 47, DK-5000 Odense, Denmark., Thisgaard H; Department of Nuclear Medicine, Odense University Hospital, Kløvervænget 47, DK-5000 Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, J.B. Winsløws Vej 19, DK-5000 Odense, Denmark.
المصدر:	Molecules (Basel, Switzerland) [Molecules] 2022 Oct 12; Vol. 27 (20). Date of Electronic Publication: 2022 Oct 12.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH:	Gallium Radioisotopes* , Neuroendocrine Tumors*/diagnostic imaging, Animals ; Mice ; Receptors, Somatostatin/metabolism ; Positron Emission Tomography Computed Tomography/methods ; Octreotide ; Tissue Distribution ; Positron-Emission Tomography/methods ; Radiopharmaceuticals
مستخلص:	Background: The somatostatin receptors 1-5 are overexpressed on neuroendocrine neoplasms and, as such, represent a favorable target for molecular imaging. This study investigates the potential of [ ¹⁸ F]AlF-NOTA-[1-Nal ³ ]-Octreotide and compares it in vivo to DOTA- and NOTA-[1-Nal ³ ]-Octreotide radiolabeled with gallium-68. Methods: DOTA- and NOTA-NOC were radiolabeled with gallium-68 and NOTA-NOC with [ ¹⁸ F]AlF. Biodistributions of the three radioligands were evaluated in AR42J xenografted mice at 1 h p.i and for [ ¹⁸ F]AlF at 3 h p.i. Preclinical PET/CT was applied to confirm the general uptake pattern. Results: Gallium-68 was incorporated into DOTA- and NOTA-NOC in yields and radiochemical purities greater than 96.5%. NOTA-NOC was radiolabeled with [ ¹⁸ F]AlF in yields of 38 ± 8% and radiochemical purity above 99% after purification. The biodistribution in tumor-bearing mice showed a high uptake in tumors of 26.4 ± 10.8 %ID/g for [ ⁶⁸ Ga]Ga-DOTA-NOC and 25.7 ± 5.8 %ID/g for [ ⁶⁸ Ga]Ga-NOTA-NOC. Additionally, [ ¹⁸ F]AlF-NOTA-NOC exhibited a tumor uptake of 37.3 ± 10.5 %ID/g for [ ¹⁸ F]AlF-NOTA-NOC, which further increased to 42.1 ± 5.3 %ID/g at 3 h p.i. Conclusions: The high tumor uptake of all radioligands was observed. However, [ ¹⁸ F]AlF-NOTA-NOC surpassed the other clinically well-established radiotracers in vivo, especially at 3 h p.i. The tumor-to-blood and -liver ratios increased significantly over three hours for [ ¹⁸ F]AlF-NOTA-NOC, making it possible to detect liver metastases. Therefore, [ ¹⁸ F]AlF demonstrates promise as a surrogate pseudo-radiometal to gallium-68.
References:	Nucl Med Biol. 2013 Jul;40(5):618-24. (PMID: 23602763) EJNMMI Radiopharm Chem. 2021 Jan 7;6(1):1. (PMID: 33411034) N Engl J Med. 2017 Jan 12;376(2):125-135. (PMID: 28076709) Bioconjug Chem. 2012 Mar 21;23(3):538-47. (PMID: 22273147) Cancer Biother Radiopharm. 2003 Aug;18(4):593-9. (PMID: 14503955) J Nucl Med. 2014 Dec;55(12):2050-6. (PMID: 25413139) Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):870-880. (PMID: 31492994) Mol Imaging Biol. 2016 Jun;18(3):368-76. (PMID: 26561028) Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):2944-2946. (PMID: 32715336) Q J Nucl Med Mol Imaging. 2010 Feb;54(1):61-7. (PMID: 20168287) J Nucl Med. 2010 Mar;51(3):454-61. (PMID: 20150268) Nucl Med Biol. 2018 Jun;61:36-44. (PMID: 29747035) Methods Mol Biol. 2014;1060:309-30. (PMID: 24037848) Cancer Biother Radiopharm. 2020 Apr;35(3):163-166. (PMID: 32196363) J Nucl Med. 2009 Jun;50(6):991-8. (PMID: 19443594) EJNMMI Radiopharm Chem. 2018;3(1):3. (PMID: 29503860) J Nucl Med. 2013 Dec;54(12):2132-8. (PMID: 24198391) Endocr Relat Cancer. 2017 Jul;24(7):R261-R274. (PMID: 28483790) EJNMMI Radiopharm Chem. 2020 Jan 29;5(1):4. (PMID: 31997090) J Nucl Med. 2014 Aug;55(8):1311-6. (PMID: 24876207)
فهرسة مساهمة:	Keywords: AlF; F-18; PET; gallium-68; neuroendocrine; octreotide
المشرفين على المادة:	56491-86-2 (1,4,7-triazacyclononane-N,N',N''-triacetic acid) 1HTE449DGZ (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid) 98B30EPP5S (Gallium-68) 0 (Gallium Radioisotopes) 0 (Receptors, Somatostatin) RWM8CCW8GP (Octreotide) 0 (Radiopharmaceuticals)
تواريخ الأحداث:	Date Created: 20221027 Date Completed: 20221028 Latest Revision: 20221030
رمز التحديث:	20221213
مُعرف محوري في PubMed:	PMC9609173
DOI:	10.3390/molecules27206818
PMID:	36296411
قاعدة البيانات:	MEDLINE

Find this article in full text from ProQuest

Full Text Finder

الوصف
تدمد:	1420-3049
DOI:	10.3390/molecules27206818